erythromycin vs ranolazine
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of erythromycin and ranolazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7 DRUG INTERACTIONS Moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin): Limit ranolazine to 500 mg twice daily. Moderate CYP3A Inhibitors Limit the dose of ranolazine to 500 mg twice daily in patients on moderate CYP3A inhibitors, including diltiazem, verapamil, erythromycin, fluconazole, and grapefruit juice or grapefruit-containing products [see Dosage and Administration (2.2) , Clinical Pharmacology (12.3) ].
E-Mycin, Ery-Tab
Ranexa
Erythromycin Topical Solution is a medicine that you put on your skin to treat acne. It contains an antibiotic to help clear up your skin.
Ranolazine extended-release tablets help treat chronic angina (chest pain). It can be used with other heart medicines.
Erythromycin Topical Solution treats acne vulgaris. This medicine helps to reduce acne on your face, neck, shoulders, chest, and back. It works by fighting the bacteria that cause acne.
Ranolazine is used to treat chronic angina, which is chest pain that keeps coming back. It can help you have fewer angina episodes. You can take this medicine with other drugs like beta-blockers or nitrates.
Erythromycin is a macrolide antibiotic. It works by stopping the growth of bacteria. This helps to reduce inflammation and clear up acne.
Ranolazine works by affecting the sodium channels in your heart cells. This helps to improve blood flow to your heart. It reduces the amount of calcium in your heart, which can help prevent angina.
- • Peeling
- • Dryness
- • Itching
- • Redness
- • Oily skin
- • Dizziness
- • Headache
- • Constipation
- • Nausea
- Drug Hypersensitivity 4,088
- Nausea 1,271
- Vomiting 1,121
- Diarrhoea 1,069
- Dyspnoea 1,023
- Death 816
- Myocardial Infarction 640
- Chest Pain 605
- Angina Pectoris 594
- Stent Placement 582
You should not use this medicine if you are allergic to any of its ingredients.
Ranolazine can cause changes in your heart's electrical activity (QT prolongation). If you have kidney problems, your doctor should check your kidney function. If you develop kidney failure, stop taking ranolazine.
It is not known if erythromycin topical solution can harm an unborn baby. Talk to your doctor if you are pregnant or breastfeeding.
It is not known if ranolazine can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if ranolazine passes into breast milk. Discuss with your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare erythromycin with
How to Read This erythromycin vs ranolazine Comparison
erythromycin is classified in the Macrolide Antibiotic drug class, while ranolazine sits within the Late Sodium Current Inhibitor (Antianginal) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, erythromycin has 8,572 submissions while ranolazine has 3,237. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to erythromycin slows down the process your body uses to get rid of ranolazine. this can cause the amount of ranolazine in your blood to rise.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for erythromycin or ranolazine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.